pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,415 catalysts · 5,159 phase readout · 2,286 8k filing · 315 pdufa · 256 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 14 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: filing×type: phase readout×type: earnings×clear all
type
  • phase readout5,159
  • 8k filing2,286
  • pdufa315
  • earnings256
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›TERMINATEDphase readoutNCT05576896: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Sponsor: Northwestern University. Phase: PHASE2. Conditions: Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07334496: A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects

Sponsor: Gan & Lee Pharmaceuticals.. Phase: PHASE1. Conditions: Biosimilarity

full page →ctgov ↗
›RECRUITINGphase readoutNCT07520162: A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

Sponsor: AstraZeneca. Phase: PHASE3. Conditions: Chronic Rhinosinusitis With Nasal Polyps

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06743646: Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Sponsor: Chigenovo Co., Ltd. Phase: PHASE3. Conditions: Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy

full page →ctgov ↗
›RECRUITINGphase readoutNCT05464888: Animal Assisted Therapy in Pediatric Dentistry

Sponsor: University of North Carolina, Chapel Hill. Phase: NA. Conditions: Anxiety

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07621861: Holy Qur'an Versus Music Sound on Sleep Quality in Children Undergoing Chemotherapy

Sponsor: Rawand Shafeeq Ali. Phase: NA. Conditions: Sleep Wake Disorders

full page →ctgov ↗
›RECRUITINGphase readoutNCT05216042: GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Cardiovascular Diseases, Natriuretic Peptides, Cardiometabolic Diseases, Energy Expenditure, Glucose Metabolism, Exercise, Obesity

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04993742: Effects of Pregnancy-Specific Anxiety on Placental Inflammatory and Oxidative Stress Response and Birth Outcomes

Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine. Phase: NA. Conditions: Placental Dysfunction, Prenatal Stress

full page →ctgov ↗
›COMPLETEDphase readoutNCT06054386: Attention Bias Modification Training for Social Phobia (ABMSP)

Sponsor: University of Wisconsin, Milwaukee. Phase: NA. Conditions: Social Anxiety Disorder

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04459273: Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Sponsor: Jonsson Comprehensive Cancer Center. Phase: PHASE1. Conditions: Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site

full page →ctgov ↗
›AVAILABLEphase readoutNCT05982873: Expanded Access to Telisotuzumab Adizutecan

Sponsor: AbbVie. Phase: . Conditions: Solid Tumors

full page →ctgov ↗
›COMPLETEDphase readoutNCT04156373: Fuerte Program for Newcomer Immigrant Youth

Sponsor: University of California, San Francisco. Phase: NA. Conditions: Trauma, Psychological, Mental Disorder in Adolescence, Adolescent - Emotional Problem

full page →ctgov ↗
›RECRUITINGphase readoutNCT05098769: A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.

Sponsor: Shengjing Hospital. Phase: . Conditions: Pulmonary Embolism and Thrombosis, Deterioration, Clinical

full page →ctgov ↗
›RECRUITINGphase readoutNCT07242469: A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE1. Conditions: Diabetes Mellitus, Type 2

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07355283: IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.. Phase: PHASE3. Conditions: Relapsed/Refractory Follicular Lymphoma

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06919783: Adapting a Health at Every Size Intervention to Obstetric Care

Sponsor: University of Massachusetts, Worcester. Phase: NA. Conditions: Weight Stigma

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07583641: A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

Sponsor: argenx. Phase: PHASE2. Conditions: Autoimmune Encephalitis (AE)

full page →ctgov ↗
›RECRUITINGphase readoutNCT06837454: French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Sponsor: Sanofi. Phase: . Conditions: Atopic Dermatitis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04691154: A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Sponsor: Liquidia Technologies, Inc.. Phase: PHASE3. Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases

full page →ctgov ↗
›RECRUITINGphase readoutNCT04889105: Exercise Therapy for PAD Using Mobile Health

Sponsor: VA Office of Research and Development. Phase: NA. Conditions: Peripheral Artery Disease

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07675005: The Prospective, Multicenter, Randomized Controlled Trial of the VentriCure Interventional Left Ventricular Assist System

Sponsor: Life Shield Medical Technology Co., LTD. Phase: NA. Conditions: Coronary Artery Disease

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07482605: Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Sponsor: Jiangmen Central Hospital. Phase: PHASE2. Conditions: Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07460505: Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure

Sponsor: National University Hospital, Singapore. Phase: NA. Conditions: Heart Failure, OSA - Obstructive Sleep Apnea

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT02502266: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04214756: Methodist Acute Pancreatitis Protocol

Sponsor: Methodist Health System. Phase: . Conditions: Acute Pancreatitis (AP)

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04562766: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Sponsor: Principia Biopharma, a Sanofi Company. Phase: PHASE3. Conditions: Immune Thrombocytopenia

full page →ctgov ↗
›COMPLETEDphase readoutNCT07243756: Gut Microbiome Pill

Sponsor: NYU Langone Health. Phase: NA. Conditions: Healthy

full page →ctgov ↗
›RECRUITINGphase readoutNCT07425756: taVNS Combined With TENS on Motor Function in Stroke

Sponsor: The Hong Kong Polytechnic University. Phase: NA. Conditions: Stroke

full page →ctgov ↗
›RECRUITINGphase readoutNCT07380256: Visual Influences on Vestibular Adaptation

Sponsor: Emory University. Phase: NA. Conditions: Vestibular Hypofunction, Binocular Vision Abnormalities, Reduced Vision

full page →ctgov ↗
›COMPLETEDphase readoutNCT03494322: EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

Sponsor: University College, London. Phase: PHASE2. Conditions: Head and Neck Cancer, Squamous Cell Carcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT06465329: A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Regeneron Pharmaceuticals. Phase: PHASE2. Conditions: Non-Small Cell Lung Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT07669402: Comparative Evaluation of the Efficacy of Letrozole, L-Carnitine, and Their Combination on Sperm Quality, Oxidative Stress, and ART Outcomes in Men With Idiopathic Oligoasthenoteratozoospermia.

Sponsor: Tehran University of Medical Sciences. Phase: PHASE2. Conditions: Idiopathic Oligoasthenoteratozoospermia, Male Infertility

full page →ctgov ↗
›WITHHELDphase readoutNCT07354802: [Trial of device that is not approved or cleared by the U.S. FDA]

Sponsor: [Redacted]. Phase: . Conditions:

full page →ctgov ↗
›RECRUITINGphase readoutNCT07209202: Fructose Intestinal Gluconeogenesis

Sponsor: Touro University, California. Phase: NA. Conditions: Healthy Participants, Obese But Otherwise Healthy Participants

full page →ctgov ↗
›COMPLETEDphase readoutNCT04991402: Obesogenic Origins of Maternal and Child Metabolic Health Involving Dolutegravir

Sponsor: Columbia University. Phase: . Conditions: HIV, Obesity, Obesity, Infant, Maternal Obesity During Childbirth, Maternal Obesity Complicating Pregnancy

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06473831: MagDI Australia Study

Sponsor: GT Metabolic Solutions, Inc.. Phase: NA. Conditions: Obesity, Type 2 Diabetes

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT00496522: Proton Beam Therapy for Chondrosarcoma

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Chondrosarcoma

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT07049822: Optimising Mammography Screening Accuracy With Blood-based Biomarkers

Sponsor: Vejle Hospital. Phase: . Conditions: Breast Cancer

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07549022: Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

Sponsor: Ankit Mangla, MD. Phase: PHASE1. Conditions: Malignant Peripheral Nerve Sheath Tumors, MPNST

full page →ctgov ↗
›COMPLETEDphase readoutNCT07370922: Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

Sponsor: Ain Shams University. Phase: PHASE2. Conditions: Transfusion Dependent Beta Thalassemia

full page →ctgov ↗
›COMPLETEDphase readoutNCT07090902: The Effect of Progressive Relaxation Exercise

Sponsor: Karabuk University. Phase: NA. Conditions: Breastfeeding, Pregnancy, Labor Pain

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03596645: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Janssen Research & Development, LLC. Phase: PHASE3. Conditions: Colitis, Ulcerative

full page →ctgov ↗
›RECRUITINGphase readoutNCT07611045: CARE Qualitative Study

Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust. Phase: . Conditions: Cardiac Surgery

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07587580: Fetal Ovarian Cysts and IOTA Terminology for Perinatal Management

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Phase: . Conditions: Fetal Ovarian Cyst, Neonatal Ovarian Cyst

full page →ctgov ↗
›RECRUITINGphase readoutNCT02945579: Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Sponsor: M.D. Anderson Cancer Center. Phase: NA. Conditions: Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT06920862: Multi-Modal Digital Interventions for Adolescent Weight Management

Sponsor: National Yang Ming Chiao Tung University. Phase: NA. Conditions: Obesity, Adolescent, Weight Change, Body, Weight Stigma

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07485062: Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes

Sponsor: Western University, Canada. Phase: PHASE4. Conditions: Type 2 Diabetes, Cognitive Decline in Older Adults

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04859946: Itacitinib for the Prevention of Graft Versus Host Disease

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Hematologic and Lymphocytic Disorder

full page →ctgov ↗
›RECRUITINGphase readoutNCT06319027: Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Sponsor: ECOG-ACRIN Cancer Research Group. Phase: PHASE2. Conditions: Glioblastoma, IDH-Wildtype

full page →ctgov ↗
›COMPLETEDphase readoutNCT06556927: The Laughter, Pregnancy, Anxiety and Llife Quality

Sponsor: Kırklareli University. Phase: NA. Conditions: Anxiety, Life Style, Gestational Diabetes, Pregnancy Related

full page →ctgov ↗
← prev
page 98 of 109
next →